31183-91-2Relevant articles and documents
Discovery of Small Molecules that Induce the Degradation of Huntingtin
Tomoshige, Shusuke,Nomura, Sayaka,Ohgane, Kenji,Hashimoto, Yuichi,Ishikawa, Minoru
, p. 11530 - 11533 (2017)
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the aggregation of mutant huntingtin (mHtt), and removal of toxic mHtt is expected to be an effective therapeutic approach. We designed two small hybrid molecules (1 and 2) by linking a ligand for ubiquitin ligase (cellular inhibitor of apoptosis protein 1; cIAP1) with probes for mHtt aggregates, anticipating that these compounds would recruit cIAP1 to mHtt and induce selective degradation by the ubiquitin-proteasome system. The synthesized compounds reduced mHtt levels in HD patient fibroblasts and appear to be promising candidates for the development of a treatment for HD.
A simple and efficient method for synthesis of benzothiazepine derivatives
Itabashi, Saori,Lu, Rong,Miyakoshi, Tetsuo
experimental part, p. 171 - 177 (2011/04/26)
A series of 1, 5-benzothiazepines were synthesized using disulfides and α, β-unsaturated carbonyl or nitrile compounds as reaction substrates. After reductive cleavage of the S-S bond of disulfides, the resulting thiols were reacted with α,β-unsaturated carbonyl or nitrile compounds to generated seven-membered heterocyclic compounds. In the presence of ammonium thioglycolate, the Michael reaction occurred between disulfides (1) and 4-methyl-3-penten-2-one to give 2, 2, 4-trymethyl-3H-1, 5-benzothiazepine derivatives in good yields. When ethyl acrylate or acrylonitrile was used as the Michael acceptor, 90-99% of (2-amino- phenylsulfanyl)propionitriles (3) and/or 92-99% of (2-amino-phenylsulfanyl) propionic acid ethyl esters (4) were produced. Subsequently, the 1, 5-benzothiazepine compounds 5 and 6 were obtained due to the cyclization reaction. The Japan Institute of Heterocyclic Chemistry.
Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3
Fink, Brian E.,Gavai, Ashvinikumar V.,Tokarski, John S.,Goyal, Bindu,Misra, Raj,Xiao, Hai-Yun,Kimball, S. David,Han, Wen-Ching,Norris, Derek,Spires, Thomas E.,You, Dan,Gottardis, Marco M.,Lorenzi, Matthew V.,Vite, Gregory D.
, p. 1532 - 1536 (2007/10/03)
A novel series of 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) inhibitors has been identified. These inhibitors, based on a dibenzazocine core, exhibited picomolar to low nanomolar inhibition of 17β-HSD3 in cell-free enzymatic as well as in cell-based transcriptional reporter assays.
